Divarasib

Dana-Farber Cancer Institute researchers are presenting multiple groundbreaking studies on head and neck, breast, and lung cancers at the 2025 AACR Annual Meeting in Chicago from April 25-30.

The global KRAS inhibitors market has experienced over 400% growth since the first approval in 2021, with four drugs now authorized for treating cancers with KRAS mutations.

Adagrasib significantly improves progression-free survival (PFS) compared to docetaxel in KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients previously treated with chemotherapy and immunotherapy.

A new clinical trial in Kenya is evaluating Roche's GDC-6036, a novel drug targeting the KRAS gene, in cancer patients.